The emergence of compounds like copyright and Semaglutide signifies a significant shift in how we approach type 2 diabetes. These new therapies belong to a class known as GLP-1 action agonists, which replicate the effects of a natural hormone that manages sugar levels and food intake. Initially, developed for diabetic conditions, their effectivenes